Th17/Treg cell balance in stable liver transplant recipients

Assadiasl, Sara; Toosi, Mohsen Nassiri; Mohebbi, Bahareh; Ansaripour, Bita; Soleimanifar, Narjes; Sadr, Maryam; Mojtahedi, Hanieh; Mosharmovahed, Banafsheh; Fazeli, Fatemeh; Nicknam, Mohammad Hossein

doi:10.1016/j.trim.2022.101540

Cited by 8 publications

(7 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…64 Similarly, a single-center study of liver transplant recipients identified a significant elevation of Th17/Treg ratio in patients undergoing acute allograft rejection compared with stable recipients and pretransplant levels. 65 Notably, there was a significant correlation between serum IL-17 levels and Th17 cell frequency. 65 CD4 + Th22 Subtype First described by Eyerich et al 66 , the differentiation of CD4 + T cells into Th22 cells is directed by IL-6, IL-1β, TNF-α, and aryl hydrocarbon receptor (AHR) ligation.…”

Section: Cd4 + Th9 Subtypementioning

confidence: 92%

“…65 Notably, there was a significant correlation between serum IL-17 levels and Th17 cell frequency. 65 CD4 + Th22 Subtype First described by Eyerich et al 66 , the differentiation of CD4 + T cells into Th22 cells is directed by IL-6, IL-1β, TNF-α, and aryl hydrocarbon receptor (AHR) ligation. 66,67 Th22 cells can be induced by plasmacytoid dendritic cells 67 and Langerhans cells.…”

Section: Cd4 + Th9 Subtypementioning

confidence: 92%

Section: Cd4 + T Cell Subsetsmentioning

confidence: 92%

See 2 more Smart Citations

An Immune Atlas of T Cells in Transplant Rejection: Pathways and Therapeutic Opportunities

2023

View full text Add to dashboard Cite

Short-term outcomes in allotransplantation are excellent due to technical and pharmacological advances; however, improvement in long-term outcomes has been limited. Recurrent episodes of acute cellular rejection, a primarily T cell–mediated response to transplanted tissue, have been implicated in the development of chronic allograft dysfunction and loss. Although it is well established that acute cellular rejection is primarily a CD4+ and CD8+ T cell mediated response, significant heterogeneity exists within these cell compartments. During immune responses, naïve CD4+ T cells are activated and subsequently differentiate into specific T helper subsets under the influence of the local cytokine milieu. These subsets have distinct phenotypic and functional characteristics, with reported differences in their contribution to rejection responses specifically. Of particular relevance are the regulatory subsets and their potential to promote tolerance of allografts. Unraveling the specific contributions of these cell subsets in the context of transplantation is complex, but may reveal new avenues of therapeutic intervention for the prevention of rejection.

show abstract

Section: Cd4 + Th9 Subtypementioning

confidence: 92%

Section: Cd4 + Th9 Subtypementioning

confidence: 92%

Section: Cd4 + T Cell Subsetsmentioning

confidence: 92%

See 1 more Smart Citation

An Immune Atlas of T Cells in Transplant Rejection: Pathways and Therapeutic Opportunities

2023

View full text Add to dashboard Cite

show abstract

“…Therefore, the Th1/Th2 ratio can influence the course of AR to some degree. Additionally, in current research, the Tregs/Th17 ratio is considered an effective predictor of LT outcomes 282,283 . Previous studies demonstrated that administering Tregs to mice with acute liver injury can ameliorate inflammation and elevate IL‐10 levels 284 .…”

Section: Immune Response To Armentioning

confidence: 99%

“…Additionally, in current research, the Tregs/Th17 ratio is considered an effective predictor of LT outcomes. 282 , 283 Previous studies demonstrated that administering Tregs to mice with acute liver injury can ameliorate inflammation and elevate IL‐10 levels. 284 Furthermore, CD4(+)CD25(+)FoxP3(+)Tregs were observed to accumulate in immunologically tolerant rats following total lymphoid irradiation.…”

Section: Immune Response To Armentioning

confidence: 99%

Role of the immune system in liver transplantation and its implications for therapeutic interventions

Chen,

Hu,

Huang

et al. 2023

MedComm

View full text Add to dashboard Cite

Liver transplantation (LT) stands as the gold standard for treating end‐stage liver disease and hepatocellular carcinoma, yet postoperative complications continue to impact survival rates. The liver's unique immune system, governed by a microenvironment of diverse immune cells, is disrupted during processes like ischemia–reperfusion injury posttransplantation, leading to immune imbalance, inflammation, and subsequent complications. In the posttransplantation period, immune cells within the liver collaboratively foster a tolerant environment, crucial for immune tolerance and liver regeneration. While clinical trials exploring cell therapy for LT complications exist, a comprehensive summary is lacking. This review provides an insight into the intricacies of the liver's immune microenvironment, with a specific focus on macrophages and T cells as primary immune players. Delving into the immunological dynamics at different stages of LT, we explore the disruptions after LT and subsequent immune responses. Focusing on immune cell targeting for treating liver transplant complications, we provide a comprehensive summary of ongoing clinical trials in this domain, especially cell therapies. Furthermore, we offer innovative treatment strategies that leverage the opportunities and prospects identified in the therapeutic landscape. This review seeks to advance our understanding of LT immunology and steer the development of precise therapies for postoperative complications.

show abstract

RAGE antagonism with azeliragon improves xenograft rejection by T cells in humanized mice.

Joshi

Wu²,

Deng³

et al. 2022

Clinical Immunology

View full text Add to dashboard Cite

Th17/Treg cell balance in stable liver transplant recipients

Cited by 8 publications

References 45 publications

An Immune Atlas of T Cells in Transplant Rejection: Pathways and Therapeutic Opportunities

An Immune Atlas of T Cells in Transplant Rejection: Pathways and Therapeutic Opportunities

Role of the immune system in liver transplantation and its implications for therapeutic interventions

RAGE antagonism with azeliragon improves xenograft rejection by T cells in humanized mice.

Contact Info

Product

Resources

About